SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending due to market volatility sparked by uncertainty surrounding the ongoing military conflict with Iran, with participants actively debating the company's fundamentals against the backdrop of broader geopolitical instability. The discussion on social platforms is highly polarized, focusing on skepticism regarding official administration announcements, concerns over economic repercussions, and intense commentary on leadership credibility.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Meta Platforms is facing a significant sell-off as investors react to two consecutive legal losses in California regarding addictive design, with community members fiercely debating whether to blame the platform's algorithms or personal responsibility. While some traders are expressing extreme bearish sentiment and fear that these rulings create a precedent for thousands of future lawsuits, others view the sharp pullback as a buying opportunity, emphasizing that the company's underlying fundamentals and revenue generation remain intact.

Madrigal Pharmaceuticals, Inc. engages in the development and commercialization of innovative therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product, MGL-3196, is used for the treatment of non-alcoholic steatohepatitis and familial hypercholesterolemia. The company was founded by Rebecca A. Taub, Frederick Bernard Craves, and Edward Chiang on March 10, 2000 and is headquartered in West Conshohocken, PA.

Madrigal Pharmaceuticals Inc

Madrigal Pharmaceuticals is trending as investors digest a wave of positive analyst upgrades and persistent M&A speculation, with the community actively debating whether the stock's long-term potential as the first-to-market MASH treatment justifies current valuations. While sentiment remains divided between those expecting a near-term buyout and those favoring a long-term hold, discussions are heavily focused on the company's ability to maintain its market lead amidst expanding competition.

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Unity Software is seeing heightened volatility and investor scrutiny as the stock faces continued selling pressure, with community sentiment split between those viewing the current valuation as a deep-value buying opportunity and others concerned by broader sector headwinds. Investors are actively debating the company's long-term pivot toward its 'Grow' and advertising segments while keeping a close watch on potential catalysts like upcoming product demos and rumors surrounding the sale of the Unity China division.

Procter & Gamble Co. engages in the provision of branded consumer packaged goods. It operates through the following segments: Beauty, Grooming, Health Care, Fabric and Home Care, and Baby, Feminine and Family Care. The Beauty segment offers hair, skin, and personal care. The Grooming segment consists of shave care like female and male blades and razors, pre and post shave products, and appliances. The Health Care segment includes oral care products like toothbrushes, toothpaste, and personal health care such as gastrointestinal, rapid diagnostics, respiratory, and vitamins, minerals, and supplements. The Fabric and Home care segment consists of fabric enhancers, laundry additives and detergents, and air, dish, and surface care. The Baby, Feminine and Family Care segment sells baby wipes, diapers, and pants, adult incontinence, feminine care, paper towels, tissues, and toilet paper. The company was founded by William Procter and James Gamble in 1837 and is headquartered in Cincinnati, OH.

Procter & Gamble Co.

Procter & Gamble is seeing active community discussion around its structural support levels near $150, with investors debating whether the stock represents a defensive value opportunity or a potential falling knife. Traders are closely monitoring the company's dividend reliability and operational efficiency plans while analyzing institutional sentiment ahead of upcoming earnings.

GraniteShares ETF Trust - GraniteShares 2x Long MU Daily ETF

GraniteShares 2x Long MU Daily ETF

MULL is seeing heavy trading activity as investors leverage it as a high-volatility vehicle to play the price action of Micron, with many users actively scalping the swings or accumulating shares on dips. The community is fiercely debating the stock's future potential, with bulls citing technical strength and upward momentum while others warn about the risks of volatility decay inherent in leveraged ETFs.

Carnival Corp. engages in the operation of cruise ships. It operates through the following business segments: North America Cruise Operations, Europe Cruise Operations, Cruise Support, and Tour and Others. The North America Cruise Operations segment includes the Carnival Cruise Line, Holland America Line, Princess Cruises, and Seabourn. Europe Cruise Operations segment consists of AIDA, Costa, Cunard, and P&O Cruises (UK). The Cruise Support segment represents port destinations and private islands for the benefit of its cruise brands. The Tour and Other segment operates hotel and transportation operations of Holland America Princess Alaska Tours. The company was founded in 1972 and is headquartered in Miami, FL.

Carnival Corp. - Ordinary Shares (Paired Stock)

Carnival Corp

Carnival Corp (CCL) is experiencing significant downward pressure as investors rotate out of travel stocks amid escalating geopolitical tensions in the Middle East and a sharp spike in crude oil prices. While the community remains deeply divided between those citing oversold valuations and record cruise demand versus those fearing a prolonged sector downturn, the stock is seeing heightened volatility as traders weigh the potential for a recovery against the threat of sustained high fuel costs.

Zebec's integrated products - real time payroll apps, on-chain payments infrastructure and networked DePIN - serve companies of all sizes, merchants and individuals and help transcend the boundaries of traditional banking and diminish the role of financial intermediaries.

Zebec Network

Zebec Network (ZBCN) is currently trending as the community actively discusses upcoming major ecosystem announcements, an anticipated partnership at the XRP Las Vegas conference, and the significance of hitting 100,000 holders. While sentiment remains divided between hopeful long-term investors focused on utility and adoption and skeptics who characterize the price action as a pump-and-dump scheme, the primary focus is on the final token unlock and its potential impact on price volatility.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

The SPY is trending as traders grapple with extreme volatility and geopolitical uncertainty, with the community actively debating whether recent "taco" announcementspresidential tweets delaying strikes on Iranian energy sitesare genuine catalysts for a recovery or merely temporary market manipulation. Investors are increasingly skeptical of these repeated deadline extensions, leading to a focus on institutional accumulation patterns versus potential technical breakdowns as the market navigates significant risk-off sentiment.

Sharplink, Inc. is an institutional-grade Ethereum treasury platform that provides public market investors with exposure to ETH. The platform focuses on Ethereum, which is used in various stablecoin, tokenized real-world asset, and decentralized finance settlement applications. This allows for native yield generation and potential network growth opportunities with ETH. The company is also involved in the online affiliate marketing business. The company was founded in 2019 and is headquartered in Miami, FL.

Sharplink Inc.

SharpLink Gaming Ltd

Sharplink Gaming is facing intense investor skepticism and volatility as stakeholders scrutinize the company's aggressive Ethereum-focused treasury strategy amid a prolonged, multi-month price decline. While some in the community advocate for a long-term holding strategy citing the accumulation of staked assets and potential institutional adoption, many others are expressing deep frustration over sustained losses and lack of clear performance milestones.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Healthcare Stocks To Consider - March 26th

UnitedHealth Group, Johnson & Johnson, Cencora, Medtronic, and Hims & Hers Health are the five Healthcare stocks to watch today, according to MarketBeat's stock screener tool. Healthcare stocks are shares of companies involved in delivering medical goods and servicessuch as pharmaceutical and biot...

What's Happening With Novo Nordisk Stock Today?

Novo Nordisk A/S (NYSE:NVO) shares are moving higher on Thursday. Hims & Hers Health Inc (NYSE:HIMS) announced it will begin offering several of the Novo's FDA approved GLP 1 medications, including...

<ul class="summary-bullets"><li>Wegovy will be initially available in 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg injection doses, with a higher 7.2 mg dose to be available later, HIMS said.</li><li>Ozempic injection pens will be available in 0.25 mg, 0.5 mg, 1 mg, and 2 mg doses.</li><li>HIMS will also introduce a weight-loss membership starting at $39 for the first month, then $149 per month thereafter.</li></ul>Hims &amp; Hers Health Inc (HIMS) grabbed retail attention on Thursday after launching a broad lineup of Novo Nordisk GLP-1 medications on its platform, including the FDA-approved Wegovy pill. The rollout comes just weeks after Novo dropped its patent infringement lawsuit against Hims related to its blockbuster weight-loss drugs.<a href="https://stocktwits.com/symbol/HIMS">HIMS stock</a> was down more than 3%, while <a href="https://stocktwits.com/symbol/NVO">NVO shares</a> climbed nearly 2% higher at the time of writing.<h2 class="st-heading-2">Wegovy To Be Available In Several Doses</h2>HIMS said that eligible patients will have access to multiple treatment options, including Wegovy in 0.25 mg, 0.5 mg, 1 mg, 1.7 mg, and 2.4 mg injection doses, and 1.5 mg, 4 mg, 9 mg, and 25 mg pill forms. A 7.2 mg injection will be available later, the company said.Ozempic injection pens will be available in 0.25 mg, 0.5 mg, 1 mg, and 2 mg doses for the management of Type 2 diabetes. It has not been approved by the FDA for weight loss.HIMS is introducing a new&nbsp;weight-loss&nbsp;membership that provides comprehensive support, including 24/7 access to healthcare providers, personalized nutrition guidance, regular check-ins, and a peer support community. Membership will start at $39 for the first month, followed by $149 per month thereafter.<h2 class="st-heading-2">Legal Battle Over Compounded Drugs</h2>Last month, Novo Nordisk filed a patent infringement lawsuit against Hims &amp; Hers after the telehealth company introduced a low-cost, compounded version of the Wegovy pill for $49 per month, claiming it contained the same active ingredient as the branded drug. Novo argued that the products violated its patents and misled consumers about safety and effectiveness, prompting the FDA to warn about the use of GLP-1 ingredients in unapproved compounded drugs.However, Novo Nordisk <a href="https://stocktwits.com/news-articles/markets/equity/hims-stock-soars-novo-nordisk-drops-patent-suit-hims-hers-partnership-ozempic/cZdVZe7RIIk">dropped</a> the lawsuit earlier this month and instead formed a partnership with Hims &amp; Hers, allowing the company to offer FDA-approved versions of Wegovy and Ozempic at more affordable self-pay prices. Hims &amp; Hers also announced it would stop marketing compounded GLP-1 drugs and transition existing patients to FDA-approved treatments.<h2 class="st-heading-2">How Did Retail Traders React?</h2>Retail sentiment for both HIMS and NVO remained in the ‘bearish’ territory over the past 24 hours.&nbsp;<figure class="image"><img src="https://news.stocktwits-cdn.com/HIMS_jpg_50a2aae200.webp" alt="HIMS.jpg" width="855" height="94"><figcaption>HIMS' Sentiment Meter and Message Volumes on March 26, 2026 | Source: Stocktwits</figcaption></figure><figure class="image"><img src="https://news.stocktwits-cdn.com/NVO_jpg_c11986072f.webp" alt="NVO.jpg" width="862" height="102"><figcaption>NVO's Sentiment Meter and Message Volumes on March 26, 2026 | Source: Stocktwits</figcaption></figure>One user said they were going long after the news came out.<stembedurl>https://stocktwits.com/turnaroundtuesdays01/message/648651986</stembedurl>Year-to-date, HIMS stock has declined by about 37%, while NVO stock has fallen by about 29%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ibrx-stock-anktiva-trial-update-bladder-cancer-phase-2-idmc/cZ3rwRfRIjw">ImmunityBio Says Phase 2 Bladder Cancer Trial Has ‘Statistical Power’ – Anktiva-BCG Advances Toward Filing</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a person holds a smartphone displaying the logo of Hims & Hers Health Inc. (NYSE: HIMS). (Photo illustration by Cheng Xin/Getty Images)

HIMS Stock In Spotlight After Hims & Hers Adds Novo’s GLP-1 Treatments To Its Platform

Eligible patients will be able to access multiple treatment options, including Wegovy in several injection doses and pill forms, as well as Ozempic injection pens.

Equity

Novo Nordisks FDA-Approved GLP-1s Now Available With Hims & Hers

Hims & Hers Health, Inc. (NYSE: HIMS) today announced that a broad assortment of Novo Nordisks FDA-approved GLP-1 medications are available to eligible customers, including the Wegovy pill, which is the only FDA-approved GLP-1 weight loss pill.1 As a part of a collaboration with Novo Nordisk, Hims...

Tempus (TEM) Down 12.9% Since Last Earnings Report: Can It Rebound?

Tempus (TEM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

HIMS vs. DOCS: Which Digital Health Stock Offers Better Upside Now?

Hims & Hers and Doximity are taking different paths in digital health, but which stock offers stronger upside now? Let's dive in.

Why Is Hims & Hers Health (HIMS) Up 38% Since Last Earnings Report?

Hims & Hers Health (HIMS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Oluyemi Okupe Sells 9,217 Shares of Hims & Hers Health (NYSE:HIMS) Stock

Hims & Hers Health, Inc. (NYSE:HIMS - Get Free Report) CFO Oluyemi Okupe sold 9,217 shares of the stock in a transaction that occurred on Friday, March 20th. The shares were sold at an average price...

Hims & Hers Health, Inc. (HIMS) Dips More Than Broader Market: What You Should Know

Hims & Hers Health, Inc. (HIMS) concluded the recent trading session at $21.34, signifying a -4.99% move from its prior day's close.

INSP vs. HIMS: Which Stock Should Value Investors Buy Now?

INSP vs. HIMS: Which Stock Is the Better Value Option?

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Alphabet $GOOGL

Robinhood $HOOD

Rocket Lab $RKLB

Sandisk $SNDK

The ticker that owned the conversation. This award honors the stock that defined the market narrative through engagement, price action, and cultural presence on the boards.

Stocktwits

Stocktwits Polls

Hims & Hers Health Inc

Investors argue that heavy short interest and limited shares available to borrow are creating a mathematical setup for a violent squeeze.

Traders are intensely focused on the long-term impact of new GLP-1 weight loss drug offerings and how these margins will influence guidance.

Many retail traders are highlighting the stock's resilience and tendency to stay green while broader markets endure significant sell-offs.

The community is divided between those waiting for a potential drop to support levels like $16 and those aggressively buying the current dip.

HIMS
Hims & Hers Health Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest HIMS News

HIMSHims & Hers Health Inc